KAVA FOR ANXIETY: WHAT THE EVIDENCE REALLY SAYS
Some encouraging studies. One important negative trial. A closer look at where kava may fit—and where it should not.
Commercial disclosure: this founder-authored guide is published by Nukava, a company that sells kava. The authors have a commercial interest in the category. This is education, not medical advice or a medically reviewed treatment recommendation. The studies below do not establish that Nukava products treat anxiety.
Can kava help with anxiety?
Kava may help some people with anxiety symptoms, but the evidence is mixed. It is not a proven treatment for generalized anxiety disorder (GAD). Feeling more relaxed for an evening is not the same as treating an anxiety disorder. NCCIH · Kava usefulness & safety · 2020 GAD trial · Sarris et al.
A small six-week trial was positive; a larger sixteen-week trial was not. NCCIH's current overview says kava does not appear helpful for GAD. If worry is affecting your sleep, work or relationships, seek professional care rather than relying on kava. 2013 GAD trial · Sarris et al. · 2020 GAD trial · Sarris et al. · NCCIH · Kava usefulness & safety · NIMH · Understanding & treating GAD
In this guide · Jump to a section
First, understand the question
When worry stops being occasional
Anxiety can be the nerves before a presentation, a temporary response to stress, or something that follows you through ordinary days. GAD involves persistent, difficult-to-control worry that interferes with life. Muscle tension, restlessness, fatigue and sleep problems can accompany it. Those categories matter: a study of short-term symptoms cannot automatically answer a question about a diagnosed disorder. NIMH · Understanding & treating GAD
There is no need to wait until things feel unbearable to ask for help. A health care professional can consider your symptoms, medications, sleep, substance use and possible physical causes, then work with you on an appropriate plan. NIMH · Understanding & treating GAD
A Pacific tradition, not a modern anxiety prescription
Kava comes from Piper methysticum, a South Pacific plant in the pepper family. Pacific communities have shared kava beverages for ceremonial and medicinal purposes for thousands of years. That cultural history deserves its own respect; it is not interchangeable with a clinical trial or proof of effectiveness for GAD. NCCIH · Kava usefulness & safety
Modern studies often use standardized extracts in tablets or capsules rather than a communal beverage. Extraction, composition and study conditions differ. An outcome with one preparation does not establish the same outcome with every root powder, concentrate or finished drink. 2013 GAD trial · Sarris et al. · 2020 GAD trial · Sarris et al.
Why researchers thought it might help
Kavalactones are compounds researchers study in connection with kava's nervous-system effects. The 2013 and 2020 trials also investigated variation in GABA transporter genes as a possible influence on response. A plausible biological pathway is a reason to investigate—not a reason to assume benefit. The larger trial did not find those gene variants predicted kava treatment response. 2013 GAD trial · Sarris et al. · 2020 GAD trial · Sarris et al.
The useful question is therefore not simply whether kava can feel calming. It is whether a defined preparation improves meaningful anxiety outcomes more than placebo, for which people, over what period, and with what risks. That is where the research gets less tidy.
The papers, at a glance
A reading aid—not a systematic review or a pooled efficacy estimate. Follow the links for the original abstracts and guidance.
| Source | Design | What it found | What to keep in mind |
|---|---|---|---|
| Cochrane review · Pittler & Ernst | Historical systematic review; 12 included trials, 7 pooled on HAM-A. | Small positive signal in older extract trials. | Authors noted limited robustness; predates the 2020 trial. |
| 2002 GAD trial · Connor & Davidson | 37 adults with GAD; 4-week randomized placebo-controlled study. | Both groups improved; no difference in the principal analysis. | Small, short study; post-hoc subgroups are exploratory. |
| 2013 GAD trial · Sarris et al. | 6-week aqueous-extract RCT; 75 enrolled, 58 in intention-to-treat analysis. | Anxiety reduction favored kava; p = 0.046. | Selected population; short follow-up; cannot exclude rare harms. |
| 2020 GAD trial · Sarris et al. | 16-week multisite aqueous-extract RCT; 171 analyzed. | No significant benefit; 1.37 HAM-A points favored placebo, p = 0.25. | One defined extract; more liver-test abnormalities and some adverse effects. |
| NCCIH · Kava usefulness & safety | Public health overview; updated April 2025. | Possible anxiety-symptom benefit; not apparently helpful for GAD. | Guidance summary, not a new clinical trial; flags liver and interaction risks. |
Sources accessed October 12, 2026. This is a focused review of the linked sources, not an exhaustive search of every kava study.
A closer read of the research
The older evidence: a signal worth testing
The Cochrane review cited as Pittler and Ernst (2003) found an anxiety-reduction signal in older placebo-controlled trials. Its available abstract describes twelve included trials and seven pooled studies using the Hamilton Anxiety scale. The authors emphasized a small effect, a relatively small evidence base, limited robustness and the need for larger trials and long-term safety work. Cochrane review · Pittler & Ernst
This review helps explain the early interest in kava. It should not be read as a current verdict incorporating all subsequent research: it predates the larger 2020 GAD trial. It also concerns kava extracts across study settings, not the clinical effectiveness of Nukava. Cochrane review · Pittler & Ernst · 2020 GAD trial · Sarris et al.
A 2002 placebo-controlled study enrolled 37 adults with DSM-IV GAD for four weeks. Both groups improved, but the principal analysis found no difference between kava and placebo. Post-hoc findings varied with baseline anxiety severity; exploratory subgroup results do not replace the main null result. This small, short trial is another reason not to present the older evidence as uniformly positive. 2002 GAD trial · Connor & Davidson
2013: positive, but smaller than the headline sounds
The six-week double-blind trial enrolled 75 participants with GAD and no comorbid mood disorder. Its intention-to-treat analysis covered 58 participants who met inclusion criteria after a one-week placebo run-in. It studied an aqueous kava extract and found a greater reduction in Hamilton Anxiety scores than placebo (p = 0.046; Cohen's d = 0.62). 2013 GAD trial · Sarris et al.
That is a genuine positive result, but it needs its denominator and timeframe attached. A small six-week study in a selected population does not establish durable benefit for the broader population. More headaches were reported with kava; liver-function tests did not differ significantly between groups. A trial this size cannot exclude rare liver injury. 2013 GAD trial · Sarris et al. · NCCIH · Kava usefulness & safety
2020: the larger trial did not confirm a GAD benefit
The multisite, sixteen-week trial analyzed 171 non-medicated participants with diagnosed GAD. It used tablets containing an aqueous extract of dried kava root, standardized to 120 mg of kavalactones twice daily. Anxiety reduction did not differ significantly from placebo: the relative 1.37-point Hamilton Anxiety difference favored placebo (p = 0.25). These are study details, not dosing instructions. 2020 GAD trial · Sarris et al.
The authors concluded that this particular extract was not effective for diagnosed GAD. A nonsignificant result is not proof that no person can ever feel benefit, but it does not support claiming that kava treats GAD. Its greater size and longer follow-up make it important counterevidence to the earlier positive result. 2020 GAD trial · Sarris et al.
Memory complaints and tremor/shakiness were more frequent with kava. Liver-function abnormalities were also more frequent, although no participant met the study's criteria for herb-induced hepatic injury. That distinction matters: absence of diagnosed injury in this trial is not a guarantee of liver safety. 2020 GAD trial · Sarris et al. · NCCIH · Kava usefulness & safety
What the mixed picture means in practice
The current NCCIH summary distinguishes possible help for anxiety symptoms from GAD, for which it says kava does not appear helpful. It notes that any effect may require several weeks. The evidence does not justify a promise of instant relief, a substitute for psychotherapy or prescribed medication, or an extrapolation to a branded product. NCCIH · Kava usefulness & safety · NIMH · Understanding & treating GAD
Safety belongs in the main story, not the fine print. NCCIH links various kava products to rare liver injury, including serious or fatal cases, and notes that some cases involved water-prepared beverages. Digestive upset, headache and dizziness are possible. Do not combine kava with alcohol or sedatives such as benzodiazepines; discuss any medication with a clinician or pharmacist first. NCCIH · Kava usefulness & safety
Avoid kava during pregnancy or breastfeeding, and seek clinical guidance if you have liver disease. Do not drive or operate machinery if drowsy, dizzy or otherwise affected; feeling mentally clear is not proof that coordination is unimpaired. Stop use and seek urgent medical attention for yellowing eyes or skin, which can signal liver disease and may occur with dark urine. NCCIH · Kava usefulness & safety · NHS · Jaundice warning signs
Real people. Different experiences.
People's reports are not uniform. Below are short attributed paraphrases of three publicly available Erowid accounts—not quotes, testimonials for Nukava, or evidence that kava treats an anxiety disorder. They were selected to show positive, mixed and negative experiences, not to estimate how common any outcome is.
These are self-selected, unverified reports with different preparations, expectations and other exposures. The original pages include risky practices; linking them is not an endorsement of their methods, doses or medication choices.
Serenity alongside physical impairment
Anonymous · Erowid · published June 19, 2000
In “Heavy but Serene,” the writer describes tranquility and a relatively clear-feeling mind, but also nausea, heavy limbs, blurred vision and difficulty walking.
Read the original account →A strongly positive personal account
SOULutions · Erowid · published October 9, 2007
In “To My Fellow Anxiety & Insomnia Sufferers,” the writer attributes relaxation and relief of anxiety symptoms to kava capsules, alongside exercise and meditation.
Read the original account →Anxiety rather than relief
Medusa · Erowid · published March 28, 2020
In “Caused Me Anxiety,” the writer describes fear, nausea, dizziness and a distressing experience rather than the relaxation expected.
Read the original account →Other ways forward
These options are not interchangeable, and this is not a head-to-head efficacy ranking. CBT and prescribed medication have established roles in GAD care. Exercise and sleep support health and treatment; kava has mixed evidence and specific safety concerns. A clinician can help choose a plan that fits your situation. NIMH · Understanding & treating GAD · NCCIH · Kava usefulness & safety
| Approach | Evidence & role | Practical tradeoffs |
|---|---|---|
| Cognitive behavioral therapy (CBT) | Well-studied psychotherapy for GAD; builds ways to respond to anxious thoughts and behaviors. Source | Time, practice, cost and access to a qualified therapist. Can be delivered in person or via telehealth. |
| Prescribed SSRIs / SNRIs | Commonly used medications for GAD; selected and monitored by a health care professional. Source | May take several weeks; possible nausea, headaches or sleep effects. Medication changes need supervision. |
| Exercise & consistent sleep | Supportive habits that can reduce symptoms alongside standard care. Source | Require regularity and adaptation to health needs. Not a replacement for treatment when anxiety interferes with life. |
| Kava | Mixed anxiety evidence; the larger GAD trial was negative. Not an established GAD treatment. Source | Liver injury risk, sedation-related interactions, digestive upset and dizziness; products differ. |
Interest is not the same as certainty
Kava is worth understanding, not overselling. Early studies give a reason for scientific interest; the larger negative trial gives a reason for restraint. Our editorial 4/10 reflects that tension, not a measurement of what will happen to you. 2013 GAD trial · Sarris et al. · 2020 GAD trial · Sarris et al.
For persistent anxiety, the stronger next step is a conversation with a qualified professional about established care. Tell them about any supplements you use. Kava should not replace that care, and no study reviewed here proves that Nukava treats anxiety. NIMH · Understanding & treating GAD · NCCIH · Kava usefulness & safety
Questions worth asking
Open a question for the longer answer.
Does kava work for generalized anxiety disorder?
It is not a proven GAD treatment. The six-week 2013 trial was positive, but the larger sixteen-week 2020 trial was not. NCCIH says kava does not appear helpful for GAD symptoms. 2013 GAD trial · Sarris et al. · 2020 GAD trial · Sarris et al. · NCCIH · Kava usefulness & safety
What does the 4/10 usefulness score actually mean?
It is a nonvalidated editorial judgment weighing trial consistency, relevance, duration and safety. It is not 40% effectiveness, a clinical rating, a probability of relief or a recommendation for an individual.
Is occasional stress the same thing as GAD?
No. GAD involves persistent worry that is difficult to control and interferes with life. A clinician assesses the pattern and possible other causes; an internet article cannot diagnose you. NIMH · Understanding & treating GAD
Can kava stop a panic attack?
The evidence reviewed here does not establish kava as an acute panic-attack treatment. Do not delay urgent care for severe, new or unexplained symptoms. Discuss recurring panic with a qualified professional.
How quickly might someone notice an effect?
NCCIH says anxiety-related effects may require several weeks. A subjective feeling after a drink is a different outcome from a sustained clinical improvement. Timing varies; there is no guaranteed onset. NCCIH · Kava usefulness & safety
What dose of kava should I take for anxiety?
This guide does not recommend a treatment dose. Research used particular standardized extracts under study conditions; those amounts cannot be translated directly into droppers, drinks or every supplement. Discuss use and risks with a clinician or pharmacist. 2013 GAD trial · Sarris et al. · 2020 GAD trial · Sarris et al. · NCCIH · Kava usefulness & safety
Do these studies prove Nukava helps anxiety?
No. They studied specific kava preparations, not Nukava's clinical effectiveness. Ingredient-level studies do not prove a finished commercial product treats anxiety.
Can I take kava with an antidepressant?
Do not assume that combination is safe. Review the specific medicine and any other supplements with a clinician or pharmacist before using kava. Do not reduce or stop prescribed medication on your own. NCCIH · Kava usefulness & safety · NIMH · Understanding & treating GAD
Can I combine it with alcohol or benzodiazepines?
No. NCCIH advises against combining kava with substances that have sedative effects, including alcohol and benzodiazepines. Other sedating medicines also warrant review. NCCIH · Kava usefulness & safety
Is kava safe for the liver?
Risk is not zero. Rare serious and sometimes fatal liver injury has been associated with various products, including some water-prepared beverages. Small trials cannot reliably exclude rare harms. Liver disease is a reason to seek medical guidance rather than self-experiment. NCCIH · Kava usefulness & safety
What warning signs should prompt medical attention?
Stop use and seek urgent medical attention for yellowing skin or eyes. Jaundice can signal liver disease and may occur with dark urine. Severe reactions, fainting or breathing difficulty also need urgent assessment. This list is not exhaustive. NHS · Jaundice warning signs
Can I drive after kava?
Do not drive or operate machinery if drowsy, dizzy or otherwise affected. Do not treat a clear-feeling mind as a guarantee of unimpaired coordination. Kava is not guaranteed to leave you fit to drive. NCCIH · Kava usefulness & safety · 2020 GAD trial · Sarris et al.
What about pregnancy or breastfeeding?
Avoid kava during pregnancy and breastfeeding. NCCIH identifies special risks in these settings. A maternity care professional can help with safer approaches to anxiety. NCCIH · Kava usefulness & safety
Are traditional drinks and extracts equivalent?
No. Composition and preparation vary, and clinical studies used specific extracts. Traditional use supplies cultural context, not a guarantee that every modern formulation is effective or safe. NCCIH · Kava usefulness & safety · 2020 GAD trial · Sarris et al.
Why not rely on positive internet reviews?
They cannot separate expectation, other exposures, preparation differences or natural symptom changes from an effect of kava. Negative reports are also incomplete. Neither kind tells us the probability of benefit or harm.
When should I seek professional help?
When anxiety starts interfering with daily life, work, sleep or relationships, talk with a health care provider. If you are in crisis in the U.S., call or text 988; call emergency services for immediate danger. NIMH · Understanding & treating GAD